NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEO
  • CUSIP: N/A
  • Web:
  • Market Cap: $702.83 million
  • Outstanding Shares: 79,237,000
Average Prices:
  • 50 Day Moving Avg: $7.74
  • 200 Day Moving Avg: $8.16
  • 52 Week Range: $6.90 - $9.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 31.68
  • P/E Growth: 2.42
Sales & Book Value:
  • Annual Revenue: $246.06 million
  • Price / Sales: 2.86
  • Book Value: $2.13 per share
  • Price / Book: 4.16
  • EBIDTA: $27.3 million
  • Net Margins: -4.92%
  • Return on Equity: 5.85%
  • Return on Assets: 3.10%
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 2.12%
  • Quick Ratio: 1.97%
  • Average Volume: 378,272 shs.
  • Beta: 1.03
  • Short Ratio: 14.59

Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Wednesday, April, 26th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.02. The company had revenue of $61.68 million for the quarter, compared to the consensus estimate of $61.26 million. NeoGenomics had a positive return on equity of 5.85% and a negative net margin of 4.92%. The company's revenue was up 3.3% on a year-over-year basis. During the same period last year, the business posted $0.03 EPS. View NeoGenomics' Earnings History.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share (EPS) guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.19. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $264.60 million.NeoGenomics also updated its Q2 guidance to $0.03-0.04 EPS.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

7 analysts have issued 1 year target prices for NeoGenomics' shares. Their predictions range from $10.00 to $12.00. On average, they expect NeoGenomics' share price to reach $11.00 in the next twelve months. View Analyst Ratings for NeoGenomics.

What are analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (5/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
  • George A. Cardoza, Chief Financial Officer
  • Robert J. Shovlin, Chief Operating Officer
  • Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
  • Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
  • Steven A. Ross, Chief Information Officer
  • Steven G. Brodie Ph.d., Vice President - Operations
  • Jennifer Balliet, Vice President - Human Resources
  • Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.41%), Artisan Partners Limited Partnership (3.12%), Next Century Growth Investors LLC (2.65%), RMB Capital Management LLC (2.15%), Janus Capital Management LLC (2.12%) and Driehaus Capital Management LLC (1.80%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Next Century Growth Investors LLC, Driehaus Capital Management LLC, Russell Investments Group Ltd., Summit Creek Advisors LLC, RMB Capital Management LLC, Millrace Asset Group Inc. and Artisan Partners Limited Partnership. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Maher Albitar, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was bought by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Gabelli Funds LLC, IronBridge Capital Management LP, Renaissance Technologies LLC, Emerald Advisers Inc. PA, Dimensional Fund Advisors LP, Cowen Prime Services LLC and Northpointe Capital LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $8.87.

MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $11.00 (24.01% upside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/28/2017BTIG ResearchReiterated RatingBuy$11.00LowView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/AView Rating Details
10/26/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 6/26/2015 forward)


Earnings History for NeoGenomics (NASDAQ:NEO)
Earnings by Quarter for NeoGenomics (NASDAQ:NEO)
Earnings History by Quarter for NeoGenomics (NASDAQ NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.18 EPS
Next Year EPS Consensus Estimate: $0.28 EPS


Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 77.52%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.08View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.00View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
DateHeadline logoFDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies - June 24 at 5:24 AM logoNeoGenomics, Inc. (NEO) Upgraded to Hold by ValuEngine - June 24 at 12:06 AM logoETFs with exposure to NeoGenomics, Inc. : June 22, 2017 - June 23 at 8:22 AM logo$63.13 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter - June 16 at 3:30 PM logoZacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.02 Per Share - June 14 at 2:04 PM logoNeoGenomics, Inc. (NEO) Receives Average Rating of "Buy" from Brokerages - June 13 at 10:51 PM logoETFs with exposure to NeoGenomics, Inc. : June 8, 2017 - June 8 at 7:41 PM logoSteven A. Ross Sells 70,833 Shares of NeoGenomics, Inc. (NEO) Stock - June 6 at 7:50 PM logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 - June 6 at 7:29 PM logoNeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : June 5, 2017 - June 5 at 8:59 AM logoNeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests - June 2 at 8:09 PM logoForm 4 NEOGENOMICS INC For: May 25 Filed by: TETRAULT LYNN A. - May 31 at 9:46 AM logoNeoGenomics, Inc. (NEO) VP Sells $25,005.00 in Stock - May 30 at 8:31 PM logoBTIG Research Reiterates "Buy" Rating for NeoGenomics, Inc. (NEO) - May 28 at 7:20 AM logoNeoGenomics, Inc. (NEO) Given a $11.00 Price Target by Cantor Fitzgerald Analysts - May 27 at 9:34 AM logoNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages - May 19 at 11:06 PM logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.02 Per Share - May 17 at 4:16 PM logoNeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer - May 15 at 10:13 AM logoNeoGenomics, Inc. (NEO) Downgraded to "Sell" at Zacks Investment Research - May 9 at 7:14 AM logoNeoGenomics (NEO) Getting Somewhat Favorable News Coverage, Report Finds - May 4 at 1:21 AM logoNeoGenomics (NEO) Receiving Somewhat Positive Press Coverage, Analysis Finds - April 30 at 3:27 PM logoNeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold" - April 28 at 8:00 PM logoNeoGenomics, Inc. (NEO) Expected to Post Quarterly Sales of $65.99 Million - April 28 at 1:16 PM logoNeoGenomics, Inc. (NEO) Rating Increased to Hold at Zacks Investment Research - April 28 at 1:04 AM
News IconBRIEF-NeoGenomics sees Q2 2017 adjusted earnings per share $0.03-$0.04 - April 28 at 12:19 AM logoNeoGenomics (NEO) Receiving Somewhat Favorable Media Coverage, Study Shows - April 27 at 10:00 PM logoNeoGenomics, Inc. (NEO) Given Consensus Rating of "Buy" by Brokerages - April 27 at 2:54 PM logoHere's Why NeoGenomics, Inc. Is Dropping Today - Motley Fool - April 27 at 9:56 AM logoEdited Transcript of NEO earnings conference call or presentation 26-Apr-17 3:00pm GMT - April 27 at 9:56 AM logo Brokerages Anticipate NeoGenomics, Inc. (NEO) Will Post Earnings of $0.01 Per Share - April 27 at 1:11 AM logoNeoGenomics reports 1Q loss - April 26 at 11:29 PM logoNeoGenomics revenues up 3% in Q1; revises 2017 guidance - Seeking Alpha - April 26 at 6:28 PM logoNeoGenomics, Inc. (NEO) Posts Earnings Results, Meets Expectations - April 26 at 4:58 PM logoHere's Why NeoGenomics, Inc. Is Dropping Today - April 26 at 1:01 PM logoNeoGenomics, Inc. (NEO) Releases FY17 Earnings Guidance - April 26 at 10:12 AM logoNeoGenomics, Inc. (NEO) Issues Q2 Earnings Guidance - April 26 at 10:12 AM logoNeoGenomics' (NEO) Buy Rating Reaffirmed at Cantor Fitzgerald - April 26 at 9:57 AM logoETFs with exposure to NeoGenomics, Inc. : April 25, 2017 - April 25 at 6:03 PM logoInvestor Network Invites You to the NeoGenomics First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, April 26, 2017 - April 25 at 6:03 PM logoNeoGenomics (NEO) Getting Favorable Media Coverage, Analysis Finds - April 24 at 9:13 PM logoNeoGenomics (NEO) Getting Very Positive Press Coverage, Report Finds - April 21 at 5:24 PM logoNeoGenomics Appoints Bill Bonello as Vice President, Treasurer ... - Yahoo Finance - April 20 at 9:35 AM logoNeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development - April 20 at 9:35 AM logoNeoGenomics, Inc. – Value Analysis (NASDAQ:NEO) : April 19, 2017 - April 19 at 6:49 PM logoNeoGenomics (NEO) Given News Impact Score of 0.31 - April 18 at 6:51 PM logoNeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : April 18, 2017 - April 18 at 10:12 AM logoNeoGenomics (NEO) Receiving Favorable News Coverage, Analysis Shows - April 15 at 12:57 PM logoNeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017 - April 14 at 6:29 PM logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share - April 5 at 4:30 PM logoNeoGenomics, Inc. (NEO) Given Average Recommendation of "Buy" by Analysts - March 30 at 2:01 PM



NeoGenomics (NEO) Chart for Monday, June, 26, 2017

This page was last updated on 6/26/2017 by Staff